Chicago, IL 的 狼瘡性腎炎 臨床試驗
9 項針對 狼瘡性腎炎 的研究正在 Chicago（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
招募中2 期
- University of Chicago, Chicago
VIBRANT: VIB4920 for Active Lupus Nephritis
招募中2 期
- University of Chicago, Department of Medicine: Rheumatology, Chicago
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
招募中2 期
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
- University of Chicago Medicine- Comer Children's, Chicago
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
招募中1/2 期
- Research Site, Chicago
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
招募中1 期
- The University of Chicago Medical Center, Chicago
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
招募中1 期
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
招募中1/2 期
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
招募中1/2 期
- Nkarta Investigational Site, Chicago
Lupus Landmark Study: A Prospective Registry and Biorepository
招募中觀察性研究
- University of Chicago, Chicago
其他城市的 狼瘡性腎炎 試驗
- New York City, NY10 項研究
- Atlanta, GA9 項研究
- Houston, TX8 項研究
- Durham, NC8 項研究
- Boston, MA7 項研究
- Philadelphia, PA7 項研究
- San Francisco, CA7 項研究
- Aurora, CO5 項研究
- Miami, FL5 項研究
- St. Louis, MO5 項研究
- Cleveland, OH4 項研究
- Los Angeles, CA4 項研究
Chicago 的其他研究
- 非小細胞肺癌61 項研究
- 乳癌58 項研究
- 癌症（所有類型）51 項研究
- 轉移性癌症45 項研究
- 前列腺癌45 項研究
- 肥胖症41 項研究
- 肺癌41 項研究
- 卵巢癌36 項研究
- 中風34 項研究
- 大腸直腸癌33 項研究
- 心臟衰竭31 項研究
- 過重28 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。